ATP5MC1 and breast carcinoma: We experimentally validated ATP5G1 and ATPIF1 as new miR-29 bona fide targets suggesting that these targets play a role in mediating miR-29’s anti-proliferative effects in LCC9 and MCF-7 breast cancer cells.